Russia’s SatRx Licenses Exclusive Rights to Pfizer’s DPP-IV Inhibitor
By Heather Cartwright
Pharma Deals Review: Vol 2012 Issue 7 (Table of Contents)
Published: 16 Jul-2012
DOI: 10.3833/pdr.v2012.i7.1780 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Pfizer has granted SatRx, a start-up company in the Russian ChemRar group, exclusive global rights, excluding China, to its DPP-IV (dipeptidyl peptidase-IV) inhibitor PF-00734200, which has been studied in Phase II trials for type 2 diabetes...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS